Welcome to our dedicated page for Heron Therapeutics news (Ticker: HRTX), a resource for investors and traders seeking the latest updates and insights on Heron Therapeutics stock.
Heron Therapeutics, Inc. (Nasdaq: HRTX) is a leading commercial-stage biotechnology company focused on enhancing patient care through the development and commercialization of innovative therapeutic solutions. Specializing in the use of its proprietary Biochronomer™ polymer-based drug delivery platform, Heron is revolutionizing the pharmaceutical landscape by converting daily injectable drugs into weekly or bi-weekly regimens.
The company's product portfolio includes APONVIE, SUSTOL, ZYNRELEF, and CINVANTI, which target unmet medical needs in both acute care and oncology settings. APONVIE is effective in preventing postoperative nausea and vomiting, offering a quick 30-second IV push that is bioequivalent to oral aprepitant. SUSTOL utilizes Heron's Biochronomer® technology to extend therapeutic levels of granisetron for over five days, aiding in the prevention of chemotherapy-induced nausea and vomiting (CINV).
ZYNRELEF, a dual-acting local anesthetic combining bupivacaine and meloxicam, is notably the first extended-release local anesthetic demonstrating superior pain management and reducing opioid use for up to 72 hours post-surgery. Originally approved by the FDA in May 2021, its indication was expanded in January 2024 to cover various soft tissue and orthopedic surgeries. Recently, Heron submitted a Prior Approval Supplement (PAS) for a Vial Access Needle to streamline ZYNRELEF's preparation process, potentially enhancing its adoption in clinical settings.
CINVANTI, an IV formulation of aprepitant, significantly reduces both acute and delayed phases of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy, improving overall patient quality of life during treatment.
Financially, Heron Therapeutics is on a robust trajectory, having implemented a cost reduction program projected to save approximately $75 million through 2025. The company has secured $30 million in equity financing and a $50 million working capital facility, aiming to achieve profitability with its current operational strategies.
Heron’s strong focus on clinical excellence and strategic partnerships, such as its recent collaboration with CrossLink Life Sciences to expand ZYNRELEF's sales network, underscores its commitment to delivering substantial value and improving patient outcomes. For more detailed information, visit herontx.com.
Heron Therapeutics (HRTX) reported Q1 2022 net product sales of $23.5 million, marking a year-over-year increase from $20 million. ZYNRELEF unit demand rose by 68%, supported by CMS's approval of a 3-year transitional pass-through status starting April 1, enabling separate reimbursements outside surgical bundle payments. Additionally, the company's oncology care franchise generated $22.4 million in net revenue, a 13% rise over the prior quarter, with full-year guidance set between $89 million and $93 million. However, net loss increased to $63.9 million, or $0.63 per share.
Heron Therapeutics (HRTX) announced a conference call for May 9, 2022, at 4:30 p.m. ET to discuss its first quarter financial results and recent business highlights. The call can be accessed via telephone or web, and an archive will be available for 60 days. The company is focused on developing best-in-class treatments aimed at fulfilling unmet patient needs in acute care and oncology. Caution is advised regarding forward-looking statements due to inherent risks and uncertainties.
Heron Therapeutics, Inc. (Nasdaq: HRTX) will participate in a fireside chat at the 21st Annual Virtual Needham Healthcare Conference on April 11, 2022, at 8:00 am PT. The event aims to discuss the company's innovative approaches to addressing unmet patient needs in acute care and oncology through best-in-class treatments. A live webcast will be available on the company's website in the Investor Resources section. For more information about Heron and its products, please visit www.herontx.com.
Heron Therapeutics announced that the Centers for Medicare & Medicaid Services (CMS) approved transitional pass-through status for ZYNRELEF, effective April 1, 2022. This status allows ZYNRELEF to be reimbursed separately in Hospital Outpatient Departments (HOPD) and Ambulatory Surgical Centers (ASC) for three years, enhancing access for patients needing postoperative pain relief. With 72% of ZYNRELEF procedures occurring in outpatient settings, this approval positions Heron advantageously against competitors. ZYNRELEF is the first dual-acting local anesthetic approved for up to 72 hours of pain relief following various surgical procedures.
Heron Therapeutics, Inc. announced that Health Canada has approved ZYNRELEF, an extended-release local anesthetic, for postoperative analgesia following specific surgeries. This product is notable as it's the only extended-release bupivacaine approved in Canada, combining bupivacaine and meloxicam to enhance pain relief while reducing opioid use. The company intends to expand ZYNRELEF's indications and reduce costs through manufacturing supplements. This approval is seen as a significant step in addressing the opioid crisis.
Heron Therapeutics, Inc. (Nasdaq: HRTX) will participate in a fireside chat at the 42nd Annual Cowen Healthcare Conference on March 7, 2022, at 11:10 am PT. The live webcast will be accessible on their website in the Investor Resources section. As a commercial-stage biotechnology company, Heron focuses on developing innovative treatments for unmet patient needs in acute care and oncology. Their advanced science and patented technologies have led to a unique portfolio aimed at enhancing standards of care. More information is available at www.herontx.com.
Heron Therapeutics, Inc. (HRTX) announced its financial results for Q4 and FY 2021, reporting net product sales of $20.7 million and $86.3 million, respectively. The net loss decreased to $54.6 million for Q4 2021, improving from $62.3 million in Q4 2020. Key highlights include the successful launch of ZYNRELEF, now covering 7 million procedures annually, with net sales reaching $2.9 million. Anticipated guidance for Q1 2022 oncology care franchise sales is $20 million to $22 million. The company aims to moderate cash usage as sales grow.
Heron Therapeutics (HRTX) announced a conference call on February 28, 2022, at 4:30 p.m. ET to discuss its fourth quarter and full year 2021 financial results along with recent business developments. The call can be accessed via phone or webcast on Heron's website. The company aims to enhance patient care through innovative treatments and is committed to addressing unmet medical needs in acute care and oncology. Further details will be available during the call and afterwards on Heron's website.
Heron Therapeutics (HRTX) announced FDA approval for a supplemental New Drug Application for ZYNRELEF, expanding its use in adults for postoperative pain management after various surgeries. This approval enhances ZYNRELEF's indication for up to 72 hours of pain relief in approximately 7 million procedures annually, positioning it as a leading alternative to opioids. The clinical data show ZYNRELEF's superior efficacy over the standard bupivacaine solution. Additionally, reimbursement for the drug now covers up to 120 million lives, broadening its market potential.
Heron Therapeutics (Nasdaq: HRTX) announced the submission of a New Drug Application (NDA) for HTX-019, an injectable emulsion of aprepitant aimed at preventing postoperative nausea and vomiting (PONV) in adults. The NDA includes data supporting the bioequivalence of HTX-019 32 mg IV injection to 40 mg oral aprepitant. This formulation offers faster and more reliable drug exposure, addressing the significant unmet need for effective PONV prevention. Aprepitant is the only NK1 receptor antagonist approved for this indication, with potential benefits for millions of surgical patients annually.
FAQ
What is the current stock price of Heron Therapeutics (HRTX)?
What is the market cap of Heron Therapeutics (HRTX)?
What products does Heron Therapeutics offer?
What is ZYNRELEF used for?
What recent financial initiatives has Heron Therapeutics undertaken?
What is the Biochronomer™ platform?
What are the recent corporate updates from Heron Therapeutics?
When was ZYNRELEF first approved by the FDA?
What is APONVIE used for?
What steps has Heron taken to achieve profitability?
How does SUSTOL help cancer patients?
Where can I find more information about Heron Therapeutics?
